For recovery enhancement, performance optimisation, or longevity goals in healthy people, until a randomised, placebo-controlled trial in a defined population with an objective primary endpoint and pharmacovigilance over a clinically meaningful duration produces data we do not currently have, we just don't have good evidence of benefit, let alone safety
GLP-1 has a short half-life of only two minutes, due to renal clearance and endogenous GLP-1 is degraded by the enzyme dipeptidyl peptidase IV (DPP-4) (2022)
Semaglutide and cagrilintide each target different pathways that affect how your body manages hunger, fullness, and metabolism
But in the same week the WHO made that endorsement, Australia's medicines regulator, the Therapeutic Goods Administration, warned the drugs could lead to potential suicidal thoughts.
References Menshanov PN, et al